Compare ClearPoint Neuro Inc (CLPT) vs Quantumscape Corp (QS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Quantumscape Corp — how do they compare? ClearPoint Neuro Inc trades at $15.65 (market cap $478.63M), while Quantumscape Corp trades at $6.45 (market cap $3.95B). The key difference: Quantumscape Corp is far larger — about 8.3× ClearPoint Neuro Inc's market cap, and ClearPoint Neuro Inc is trading nearer its 52-week high, Quantumscape Corp nearer its low. Which is the better fit depends on your goals.
| CLPT | QS | |
|---|---|---|
Market Cap | $478.63M | $3.95B |
Sector | Health | Consumer Cyclical |
52-Week High | $29.60 | $18.44 |
52-Week Low | $8.66 | $5.96 |
Enterprise Value | $506.63M | $3.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
QuantumScape (QS) trades at $6.28, down 4.56% today, with a bearish technical outlook and negative profitability metrics. The company reported a net loss of $435.05M in 2025 and relies on financing cash flows to fund operations. Recent news highlights a joint research agreement with Honda, providing a potential catalyst for its solid-state battery technology development.
The outlook remains speculative with high execution risks as QS transitions from R&D to commercialization. Analyst sentiment is cautious with 73% hold ratings. Investment opportunity hinges on successful battery commercialization, but risks include persistent losses, competitive threats, and reliance on external funding.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
